Connect your AI

Maze Therapeutics, Inc. MAZE Q1 2025 Annual earnings

Reported May 14, 2025 · Before market open

Diluted EPS-$1.15Miss by $0.39

EPS estimate-$0.76

Next report

Aug 11, 2026 (In 4 weeks)

Revenue estimate$2.9M

EPS estimate-$0.76

Financials

Q1 2025

Income statement

Operating income-$35.4M-26.4%

Net income-$32.8M-0.9%

EPS (diluted)-$1.15+91.7%

Balance sheet

Cash & equivalents$294.4M+880%

Total debt$25.8M—

Total equity$292.1M—

Total assets$332.8M—

Cash flow

Operating cash flow-$29.5M-25.9%

CapEx$299.0K+7.2%

Free cash flow-$29.8M-25.7%

Segments

By geography

US-—

Versus estimates

Revenue

Q1 2026$20.0MBeat by $9.4M

Diluted EPS

Q1 2026-$0.45Miss by $0.02 Q4 2025-$0.65Beat by $0.08 Q3 2025-$0.66Beat by $0.08 Q2 2025-$0.77Beat by $0.02

Q1 2025-$1.15Miss by $0.39

Q4 2024-$18.32Miss by $18.77

Ask the moment Maze Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Harbor at dusk

Questions, answered.

When did Maze Therapeutics, Inc. report Q1 2025 earnings?: Maze Therapeutics, Inc. (MAZE) reported Q1 2025 earnings on May 14, 2025 before market open.
What were Maze Therapeutics, Inc.'s Q1 2025 revenue and EPS?: Maze Therapeutics, Inc. reported diluted EPS of $-1.15 for Q1 2025.
Did Maze Therapeutics, Inc. beat estimates in Q1 2025?: EPS missed the consensus estimate of $-0.76 by $0.39.
Where can I find Maze Therapeutics, Inc.'s Q1 2025 SEC filings?: You can read the 10-K periodic report (0000950170-25-047208) directly on SEC EDGAR. The filing index links above go to sec.gov.